Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...

Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...

“High quality, large-scale, fit-for-purpose datasets” continues to be the tagline for artificial intelligence (AI) models aiming to achieve scalable drug discovery to novel targets. While troves of ...

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug ...

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...